Article Versions Notes

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers. 2021; 13(12):2882. https://doi.org/10.3390/cancers13122882

Bauman, Julie E., Jonathan Harris, Ravindra Uppaluri, Min Yao, Robert L. Ferris, Josephine Chen, Richard C. Jordan, Nikhil P. Joshi, Srinivas Jujjuvaparu, Dukagjin M. Blakaj, and et al. 2021. "NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer" Cancers 13, no. 12: 2882. https://doi.org/10.3390/cancers13122882

Bauman, J. E., Harris, J., Uppaluri, R., Yao, M., Ferris, R. L., Chen, J., Jordan, R. C., Joshi, N. P., Jujjuvaparu, S., Blakaj, D. M., Henson, C., Sheqwara, J., Mell, L. K., Sen, N., Clump, D. A., Garg, M. K., Yilmaz, E., Torres-Saavedra, P., & Le, Q.-T. (2021). NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers, 13(12), 2882. https://doi.org/10.3390/cancers13122882